[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Personalis Inc (PSNL)

Personalis Inc (PSNL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,444,103
  • Shares Outstanding, K 104,721
  • Annual Sales, $ 69,650 K
  • Annual Income, $ -81,270 K
  • EBIT $ -103 M
  • EBITDA $ -96 M
  • 60-Month Beta 2.23
  • Price/Sales 20.15
  • Price/Cash Flow N/A
  • Price/Book 5.51

Options Overview Details

View History
  • Implied Volatility 114.81% (-10.25%)
  • Historical Volatility 93.79%
  • IV Percentile 8%
  • IV Rank 5.77%
  • IV High 494.16% on 03/30/26
  • IV Low 91.57% on 05/22/26
  • Expected Move (DTE 15) 2.08 (15.29%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,000
  • Volume Avg (30-Day) 1,144
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 19,172
  • Open Int (30-Day) 20,511
  • Expected Range 11.54 to 15.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 1
  • High Estimate $-0.25
  • Low Estimate $-0.25
  • Prior Year $-0.23
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.08 +50.00%
on 06/09/26
14.24 -4.35%
on 07/02/26
+2.48 (+22.26%)
since 06/02/26
3-Month
4.95 +174.87%
on 04/29/26
14.24 -4.35%
on 07/02/26
+7.04 (+106.99%)
since 04/02/26
52-Week
3.84 +254.69%
on 08/06/25
14.24 -4.35%
on 07/02/26
+6.11 (+81.48%)
since 07/02/25

Most Recent Stories

More News
Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Regulatory milestone for specimen collection kits enables global deployment of Personalis’ ultrasensitive MRD detection (Next Personal®) for drug development programs

PSNL : 13.62 (-1.23%)
Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

NeXT Personal® MRD test showed 100% sensitivity for CRC recurrence during surveillance and 82% landmark sensitivity 4 weeks post-surgery Ultrasensitive...

PSNL : 13.62 (-1.23%)
Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Abstracts span six cancer types, including new data on single-digit parts-per-million ctDNA detection

PSNL : 13.62 (-1.23%)
Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Expanded coverage enables Medicare beneficiaries with Stage II-III TNBC or HER2+ breast cancer to access ultrasensitive MRD testing to monitor response to neoadjuvant therapy

PSNL : 13.62 (-1.23%)
Personalis to Participate in Upcoming Investor Events

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be participating in the following investor events: ...

PSNL : 13.62 (-1.23%)
Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Expanded coverage, supported by published data from the Vall d’Hebron Institute of Oncology (VHIO), enables Medicare beneficiaries receiving immunotherapy to access ultrasensitive MRD testing to monitor...

PSNL : 13.62 (-1.23%)
Personalis Q1 Earnings Call Highlights

Personalis (NASDAQ:PSNL) reported first-quarter 2026 revenue of $15.5 million as management said the company is prioritizing growth in its clinical minimal residual disease, or MRD, testing business and...

PSNL : 13.62 (-1.23%)
Personalis: Q1 Earnings Snapshot

Personalis: Q1 Earnings Snapshot

PSNL : 13.62 (-1.23%)
Personalis Reports First Quarter Results and Recent Highlights

Clinical test volume surged 258% year-over-year and 26% sequentially to 7,815 tests in Q1 M edicare coverage secured for lung cancer surveillance, providing a...

PSNL : 13.62 (-1.23%)
Personalis Prepares to Explain Why Volume Growth Hasn't Found Revenue Yet

Barchart Research What to Expect from PSNL Earnings PSNL Generated May 6, 2026 Current Price $6.07 EPS Estimate $$-0.23 Consensus Rating Moderate Buy Average Move 13.12% Personalis Prepares to Explain...

PSNL : 13.62 (-1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.

See More

Key Turning Points

3rd Resistance Point 15.17
2nd Resistance Point 14.70
1st Resistance Point 14.16
Last Price 13.62
1st Support Level 13.16
2nd Support Level 12.69
3rd Support Level 12.15

See More

52-Week High 14.24
Last Price 13.62
Fibonacci 61.8% 10.27
Fibonacci 50% 9.04
Fibonacci 38.2% 7.81
52-Week Low 3.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.